Mayo Clinic SPORE in Pancreatic Cancer

描述（由申请人提供）：胰腺癌马约诊所孢子已经建立了一个强大的环境，以促进我们有才华的研究人员进行高质量的研究。我们的目标是在基础/临床/人口研究中应用创新技术和资源，以实现预防，早期发现和治疗的最佳策略，并提高这种毁灭性恶性肿瘤的生存率。SPORE的目标是：1）提供科学的领导和组织，以维持和支持优秀的转化胰腺癌（PC）研究; 2）提供组织基础设施，以促进沟通，促进SPORE研究人员和更大的研究社区之间的互动; 3）提供资源，以开发转化PC研究中的创新研究项目; 4）促进转化PC研究中的职业发展;和5）通过对SPORE研究计划和项目进行严格的内部审查，并由杰出的外部顾问小组进行定期审查和支持，确保研究的卓越性。我们已经开发了一个响应的基础设施，催生了创新的研究和跨学科的互动，吸引了致力于调查。马约诊所每年接诊约725例PC患者，占美国所有PC病例的1.7%。四个核心（行政、生物统计、临床研究和组织）将提供支持。项目1（新）将确定NFAT和NFAT依赖性靶基因和作用，并使用环孢菌素A和吉西他滨-abraxane进行I期研究。项目2（新）将确定NAD在PC中的作用，并在临床前研究中使用小分子SIRT 1激活化合物，以及使用SRT 3025与吉西他滨和abraxane的I期试验。项目3（继续）将使用先天免疫的激活和化疗可以协同治疗胰腺癌的研究结果，进行将TLRS激动剂VentiRx-2337与环磷酰胺组合作为FOLFIRINOX后的二线疗法的I-II期试验，优化针对PC相关MUC 1的疫苗。项目4（新）将确定DNA修复在PC中的作用，并在PARP抑制剂rucaparib治疗化疗难治性PC的II期研究中针对双链DNA修复缺陷患者进行个性化治疗。

DESCRIPTION (provided by applicant): The Mayo Clinic SPORE in Pancreatic Cancer has built a robust environment to facilitate high quality research by our talented investigators. Our goal is to apply innovative technologies and resources in basic/clinical/population research to achieve the best strategies for prevention, early detection and therapy and increase survival of this devastating malignancy. The SPORE aims to: 1) Provide the scientific leadership and organization to sustain and support outstanding translational pancreatic cancer (PC) research; 2) Provide the organizational infrastructure to facilitate communication and promote interactions among SPORE investigators and the larger research community; 3) Provide resources to develop innovative research projects in translational PC research; 4) Foster career development in translational PC research; and 5) Assure excellence of research through a rigorous internal review process of the SPORE research programs and projects, with periodic review and support from a panel of outstanding external advisors. We have developed a responsive infrastructure that has spawned innovative research and interdisciplinary interactions, attracting committed investigators. Mayo Clinic sees -725 PC patients yearly, constituting 1.7% of all PC cases in the US. Four cores (Administrative, Biostatistics, Clinical Research, and Tissue) will provide support. Project 1 (new) will identify NFATs and NFAT-dependent target genes and roles, and conduct a Phase I study using cyclosporine A and gemcitabine-abraxane. Project 2 (new) will establish the role of NAD in PC, and use small molecule SIRT1 activating compounds in preclinical studies as well as a Phase I trial using SRT3025 with gemcitabine and abraxane. Project 3 (continuing) will use pursue findings that activation of innate immunity and chemotherapy can synergize curatively against pancreatic cancer, perform Phase l-ll trials which combines the TLRS agonist VentiRx-2337 with cyclophosphamide as second line therapy after FOLFIRINOX, optimizing a vaccine against PC-associated MUC1. Project 4 (new) will identify roles of DNA repair in PC and target patients with double-stranded DNA repair defects for individualized treatment in a Phase II study of the PARP inhibitor rucaparib in chemotherapy refractive PC.